Guggenheim initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan: Buy Rating Reiterated on 2026 Clinical Catalysts and Undervalued Pipeline Upside
- Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
- Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook
- Cullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley
- Cullinan Therapeutics provides corporate update, anticipated 2026 milestones